Addition Therapeutics emerged from stealth to commercialize a Precise RNA‑Mediated Insertion of Transgenes (PRINT) platform that uses retrotransposon biology delivered in lipid nanoparticles to insert genes. The company launched publicly and outlined an all‑RNA, LNP‑based gene therapy approach aimed at persistent transgene integration without DNA vectors. Addition also closed a large financing: the spinout reported a $100M+ funding round (reported as $106.5M), backing its development and IND‑enabling work. The startup said the approach could sidestep certain limitations of traditional viral gene therapy by using RNA‑encoded insertion machinery. Investors and partners will scrutinize integration specificity and long‑term safety; Addition’s positioning as an LNP/RNA gene‑insertion contender adds a new vector to debates over durable, non‑viral gene therapies.